FOSUN HEALTH Logo

Multiple Sclerosis (MS) Treatment

catalogue

Multiple Sclerosis (MS) Treatment

Multiple Sclerosis (MS) Treatment

Treatment in this condition is three different jobs, and the reason to separate them at the outset is that each is regularly presented as though it were the others. The first is treating the episode : shortening a relapse while it is happening, which is a matter of days. The second is altering the course : a therapy taken continuously for years, aimed at what accumulates rather than at what is happening this week. The third is treating the symptoms and keeping function — spasticity, pain, fatigue, bladder, mood, and the practical work of staying independent — which is where most of a day's cost sits and which is most often left to a person to arrange alone. None of the three replaces another, and a plan that contains only the first is a plan that has not been finished. This page sets out what each involves, what the longer commitments require in monitoring, how the choice is actually made, and what the months and years afterwards consist of.

Treating the relapse

What is given for a relapse is given for the episode, and the sentence worth hearing at the beginning rather than discovering halfway through is this: it makes recovery happen sooner, not more completely. The person gets back to where they were going faster; where they end up is largely unchanged. That is a genuine benefit — a fortnight of not being able to see properly, or of a leg that will not work, is a long time — and it is not the same as altering the disease.

The usual first treatment is a short course of high-dose corticosteroid. What it does is damp the inflammation at the lesion. What it requires while it is being given is attention to blood sugar, blood pressure, sleep and mood, and a stomach that is protected where that is warranted. What its own adverse effects are, including with repeated courses — bone density, glucose tolerance, cataract risk with frequent use, and the mood disturbance that families notice before clinics do — belongs in the first conversation rather than the fourth. Where a severe relapse has not responded, plasma exchange is the second-line option, and it is used in acute inflammatory episodes where the disability is significant; it is a hospital procedure with its own requirements rather than a next tablet.

Three other things belong in the same window and are not treatment in the usual sense. The first is a urinary infection being looked for and treated, because a relapse and a urine infection worsen each other and a pseudo-relapse from infection is the commonest thing mistaken for the real one. The second is the deficit being recorded rather than described, so that what recovery happens is a measurement rather than an impression. The third is the question of why now — was there an infection, has a treatment been stopped or changed, is this the first episode or the fifth — because the answer changes what is discussed at the follow-up rather than only what happens this week.

What should not happen is the reverse: a relapse that is mild being treated with steroids because steroids are available, or a relapse that is disabling being watched because the last one got better on its own. Both are decisions about the person in front of the clinician rather than about the scan, and both are reasonable questions to ask about.

The therapy that aims at the course

Disease-modifying therapy is taken continuously, for years, by people who often feel entirely well. That is the difficult part of it, and it is worth being honest about the shape of the decision: a person is asked to accept a medicine with real monitoring requirements and real risks in exchange for an effect they will not feel, against a disease whose effects they may also not feel yet.

What these medicines do is reduce the frequency of relapses and the formation of new lesions. Some of them also slow the accumulation of disability, and which ones do is part of the conversation rather than a general statement. What they do not do is repair damage that has already happened, cure the condition, or reliably stop a progressive course once it has begun. Saying that plainly is better than implying a treatment exists for the part that has already accumulated — which is precisely why the third job on this page, treating the symptoms and keeping function, is not a consolation prize.

What a person takes on alongside the medicine is the part most often under-described. Each agent has its own monitoring: blood tests at defined intervals, imaging at defined intervals, and for some of them specific surveillance for particular risks — including the risk of progressive multifocal leukoencephalopathy with some of the higher-efficacy agents, which is why antibody status and scanning schedules are part of the arrangement rather than optional extras. Each also has its own adverse effects, its own route and frequency, and its own implications for vaccination and for pregnancy.

Two sentences close this section, and both are worth being able to say. No medicine is presented here as one this hospital routinely holds. And any medicine recommended that is not given within this pathway is named at the outset, before any payment is discussed — not at the end of a workup. Where the honest answer is that starting treatment now would not change the outcome, or that the diagnosis is not yet secure enough to justify it, that is said as plainly as the alternative.

How the choice is actually made

It is not made by ranking medicines against each other, and it is worth saying why: the comparison that matters is not between two drugs but between a drug and a person's circumstances. What follows is what is actually weighed.

Consideration What it decides
How active the disease has been What was seen on imaging, how recently, and whether there have been clinical episodes — which sets how much weight the efficacy side of the balance carries
What the person can sustain in monitoring How often blood tests are needed, how often imaging is needed, and whether that is compatible with where the person lives and works
The risk profile of the agent Risks stated one at a time rather than as a category, including the specific infection risks that carry their own surveillance
Route and frequency Tablet, injection or infusion, and how often — which is a decision about a life rather than about pharmacology
Pregnancy and family planning Whether the medicine can be continued through conception and pregnancy, whether it needs a washout, and what the plan is for relapses in the postpartum period
Vaccination Which vaccines are needed before starting, and which are not safe once immunosuppressed — which is a reason the conversation happens before the prescription
Everything else the person is taking Interactions, and the other conditions that make one risk more or less acceptable than another

What follows from that table is that the choice is revisited rather than made once. A medicine that was right at thirty may not be right at forty with a different scan, a different job, or a different plan for children. The interval at which it is reviewed is part of the prescription, and so is the question of what would prompt a change — a new lesion, a clinical relapse, an adverse effect, or a change in circumstances. Two things should never happen: a medicine being changed because a scan showed something without anyone explaining what it showed, and a person stopping a medicine without a plan because nobody had told them that stopping some of them has a rebound attached.

Treating the symptoms rather than the disease

This is the job that most affects a day, and the one most often left to a person to arrange for themselves. None of what follows alters the disease. All of it changes what a day costs, and most of it is available. The point of setting it out as a list is that each item should be asked about at a review rather than volunteered years later.

Symptom What is done What it is not
Spasticity and cramps Stretching and positioning first, then medicines that reduce tone, and in selected cases focal injection into an overactive muscle Not always worth removing entirely. Some stiffness is what lets a person stand and transfer, and removing it can remove function with it
Neuropathic pain The medicines used for nerve pain rather than the ones used for nociceptive pain, and the source — a tight muscle, a painful posture — treated alongside Not a sign the disease is active, and not something to be endured because the scan is unchanged
Fatigue Structural measures first: cooling, planning the day, treating sleep, pain, low mood and deconditioning; medication is a modest second line Not solved by resting more. Deconditioning makes it worse, which is why graded activity is part of the treatment rather than opposed to it
Bladder Establishing which kind it is — overactive, underactive, or both — before anything is prescribed; timed voiding, pelvic floor work, and medicines or self-catheterisation where indicated Not managed by drinking less, which concentrates the urine, worsens urgency and invites the infections that cause pseudo-relapses
Bowel Fibre, fluid, timing and routine, with a ladder of measures above them Not a topic to be raised privately years later. It is part of the same review as the bladder
Mood Named and treated in its own right — psychological therapy, medication, or both — rather than as a consequence to be tolerated Not weakness, and not a reason to attribute every physical symptom to it. Both directions of that error are common and both cost years
Heat sensitivity Cooling strategies, timing, and clothing — a management plan rather than a medicine Not a relapse. Treating it with steroids is treating a temperature with an immunosuppressant

The pattern across all seven is the same: the intervention is chosen for the symptom, and it works whether or not the disease is active. Which is why a review that only asks about new lesions leaves most of what a day costs entirely unaddressed — and why the follow-up page sets out these items as things to be asked about by name.

What rehabilitation actually does

Rehabilitation does not treat the disease, and that is the first thing to say because it is the reason it gets under-used: it cannot be measured in lesions, so it is easy to file as optional. What it treats is function — what a person can do, for how long, and with how much help — and on that measure it is the intervention with the most visible effect on a day.

Three things make up most of it. The first is strength and conditioning: weakness and deconditioning travel together in this condition, and much of what looks like disease progression is the second rather than the first. A graded programme increases what is available, and the increase is real even though nothing on the scan has changed. The second is balance, gait and the mechanics of transferring — stairs, a bath, a car, a kerb — which is where independence is actually won or lost, and where an hour with a physiotherapist is worth more than any number of consultations. The third is energy and the planning of a day: which is occupational rather than physical, and which is what keeps someone in work.

Alongside those, the two that get missed. The first is the equipment and the environment — a rail, a chair of the right height, a route with a bench on it — which costs very little and is most often supplied after a fall rather than before one. The second is the review date: rehabilitation is a programme with a reassessment attached, not a course of six sessions that ends. And the honest statement to close it: it does not slow the disease, and saying so is what stops it being oversold. It changes what the disease costs, which is a different and smaller-sounding claim and a considerably more useful one.

What the months and years contain

The acute episode is a fortnight. What follows is the rest of it, and it is the part most often left unstructured — which is why families experience it as something going wrong rather than as something nobody had arranged.

What the months contain is a series of questions rather than a series of treatments. Has the episode left anything behind, and is that residue or is it still settling? Is the fatigue new, or has it been there and never asked about? Is the bladder behaving differently, and is there an infection behind it? Has work been changed, and by how much? Is the current medicine still the right one, given what the last scan showed and what the person's life now looks like? Each of those has an answer, and none of them is answered by a scan alone.

What the years contain is the review, and the review is worth structuring deliberately. Imaging at an interval that has a reason behind it rather than a habit. Symptoms asked about by name — fatigue, heat, thinking, bladder, bowel, mood, pain, sexual function — because they are asked about or they do not happen. Function measured rather than described: how far, how long, what has been given up. And a written answer to the question that families actually carry, which is not 'how long' but what would change the plan.

One last thing, said plainly because it is the sentence people are most often left without: no one can tell an individual how this will go. What can be given instead is a plan — what will be measured, at what interval, what would change the treatment, and what the person can do themselves. That is a smaller thing than a prognosis and a considerably more useful one, and how it is structured is set out on the prevention page.

Frequently Asked Questions

Do steroids for a relapse change the long-term course?

They shorten the relapse, and they do not change the disease. That is worth saying plainly because it is the single most often misunderstood thing about relapse treatment. High-dose corticosteroids speed up recovery from the episode — the recovery happens sooner, not more completely. They do not reduce how much accumulates afterwards. The treatment that aims at the long-term course is a different one, it is taken continuously rather than at the time of an episode, and the two should never be presented as alternatives to each other.

Why would I start long-term treatment if I feel well?

Because the things the treatment is aiming at are frequently happening without being felt. New lesions appear on scans in people who have noticed nothing, and by the time a symptom appears there has usually been damage already. The decision to start is a balance rather than a rule: what is known about the person's disease activity, what the treatment requires in monitoring, what its risks are, and the person's own circumstances — including whether they are planning a pregnancy. It is a decision made with someone rather than for them, and it is revisited rather than made once.

Can I stop my treatment if I have been well for years?

Not on your own, and this is one of the few places where the wording should be blunt. Some disease-modifying therapies are associated with a return of disease activity — sometimes sharply, and sometimes worse than before — when they are stopped, particularly after several years. Others can be stopped with less of that risk, and in some people who have been stable for a long time, stopping is a reasonable conversation. What decides it is which medicine it is, how long it has been taken, what the recent scans show, and the person's age and plans. It is a planned decision with a team rather than a decision taken by running out of tablets.

What is actually treated, if nothing can be cured?

A great deal, and it is worth separating the three jobs because they are routinely run together as one encouraging sentence. The first is treating the episode. The second is altering the long-term course. The third — and the one that most affects a day — is treating the symptoms: spasticity, pain, fatigue, bladder function, mood, and the practical business of keeping someone walking, working and independent. None of those three is a substitute for the others, and the third is the one most often left to a person to arrange for themselves.

Find out whether the plan contains all three jobs, and which one is missing

Send the imaging with its reports in date order, the list of what has been given and for how long, any monitoring results that exist, and a short account in your own words of what has changed since the last plan — including the symptoms that no scan would show. Our team will return a written opinion on whether the current plan is aimed at the right target, what its monitoring requirements are, and what would be worth discussing before anything is changed.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*